|
gptkbp:instanceOf
|
gptkb:drug
opioid
|
|
gptkbp:administeredBy
|
gptkb:naloxone
|
|
gptkbp:approvedBy
|
1981
|
|
gptkbp:ATCCode
|
N07BC01
|
|
gptkbp:bioavailability
|
sublingual: 30-50%
|
|
gptkbp:brand
|
gptkb:Belbuca
gptkb:Suboxone
gptkb:Subutex
gptkb:Butrans
|
|
gptkbp:canCauseDependence
|
yes
|
|
gptkbp:canCauseWithdrawal
|
yes
|
|
gptkbp:CASNumber
|
52485-79-7
|
|
gptkbp:chemicalFormula
|
C29H41NO4
|
|
gptkbp:contraindication
|
paralytic ileus
severe respiratory depression
acute alcoholism
|
|
gptkbp:controlledSubstanceSchedule
|
gptkb:Schedule_III_(US)
|
|
gptkbp:developedBy
|
gptkb:Reckitt_&_Colman
|
|
gptkbp:discoveredIn
|
1966
|
|
gptkbp:eliminationHalfLife
|
24-60 hours
|
|
gptkbp:excretion
|
urine
bile
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
buprenorphine
|
|
gptkbp:legalStatus
|
gptkb:Rx-only_(EU)
gptkb:Class_C_(UK)
gptkb:Schedule_8_(Australia)
prescription only
Rx-only (US)
Rx-only (Canada)
Rx-only (Brazil)
Rx-only (India)
Rx-only (Japan)
Rx-only (New Zealand)
Rx-only (Russia)
Rx-only (South Africa)
Rx-only (Sweden)
Rx-only (Switzerland)
Rx-only (Turkey)
Rx-only (Ukraine)
|
|
gptkbp:mechanismOfAction
|
antagonist at kappa-opioid receptor
partial agonist at mu-opioid receptor
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
467.64 g/mol
|
|
gptkbp:pregnancyCategory
|
C (US)
B3 (Australia)
|
|
gptkbp:proteinBinding
|
96%
|
|
gptkbp:PubChem_CID
|
644073
DB00921
|
|
gptkbp:routeOfAdministration
|
injection
transdermal
sublingual
buccal
|
|
gptkbp:sideEffect
|
nausea
constipation
headache
sweating
insomnia
respiratory depression
|
|
gptkbp:UNII
|
33CM23913M
|
|
gptkbp:usedFor
|
pain management
opioid use disorder
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:CYP3A4
|
|
gptkbp:bfsLayer
|
5
|